Wealth Enhancement Advisory Services LLC Sells 535 Shares of Invesco Pharmaceuticals ETF $PJP

Wealth Enhancement Advisory Services LLC decreased its position in shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP) by 6.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,462 shares of the company’s stock after selling 535 shares during the quarter. Wealth Enhancement Advisory Services LLC owned 0.26% of Invesco Pharmaceuticals ETF worth $607,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. N.E.W. Advisory Services LLC bought a new position in Invesco Pharmaceuticals ETF in the 1st quarter valued at approximately $75,000. Valley National Advisers Inc. bought a new stake in Invesco Pharmaceuticals ETF during the 1st quarter worth approximately $204,000. Focus Partners Advisor Solutions LLC bought a new stake in shares of Invesco Pharmaceuticals ETF in the 1st quarter worth $208,000. Jones Financial Companies Lllp grew its stake in Invesco Pharmaceuticals ETF by 11.6% in the 1st quarter. Jones Financial Companies Lllp now owns 2,428 shares of the company’s stock valued at $210,000 after purchasing an additional 252 shares during the period. Finally, Intelligence Driven Advisers LLC bought a new position in shares of Invesco Pharmaceuticals ETF during the 2nd quarter valued at approximately $431,000.

Invesco Pharmaceuticals ETF Stock Up 1.3%

Shares of NYSEARCA:PJP opened at $95.65 on Friday. Invesco Pharmaceuticals ETF has a twelve month low of $72.25 and a twelve month high of $95.88. The company has a 50-day moving average price of $89.83 and a two-hundred day moving average price of $83.87. The firm has a market capitalization of $273.56 million, a PE ratio of 15.59 and a beta of 0.66.

About Invesco Pharmaceuticals ETF

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.